Free Trial

Lyell Immunopharma (LYEL) Competitors

Lyell Immunopharma logo
$0.70 +0.04 (+6.17%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$0.70 +0.00 (+0.61%)
As of 02/21/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LYEL vs. ABUS, IMTX, TYRA, CRMD, SANA, RAPP, MNMD, CGEM, PHAR, and SEPN

Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Arbutus Biopharma (ABUS), Immatics (IMTX), Tyra Biosciences (TYRA), CorMedix (CRMD), Sana Biotechnology (SANA), Rapport Therapeutics (RAPP), Mind Medicine (MindMed) (MNMD), Cullinan Therapeutics (CGEM), Pharming Group (PHAR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

Lyell Immunopharma vs.

Lyell Immunopharma (NASDAQ:LYEL) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.

Lyell Immunopharma has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500.

Arbutus Biopharma has higher revenue and earnings than Lyell Immunopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyell Immunopharma$130K1,574.74-$234.63M-$0.79-0.89
Arbutus Biopharma$18.14M35.76-$72.85M-$0.43-7.96

Arbutus Biopharma has a net margin of -1,137.65% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Arbutus Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Lyell Immunopharma-323,792.09% -34.64% -30.02%
Arbutus Biopharma -1,137.65%-68.18%-51.55%

Lyell Immunopharma presently has a consensus target price of $1.00, indicating a potential upside of 42.71%. Arbutus Biopharma has a consensus target price of $5.50, indicating a potential upside of 60.68%. Given Arbutus Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Arbutus Biopharma is more favorable than Lyell Immunopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyell Immunopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Arbutus Biopharma
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Arbutus Biopharma received 421 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 71.08% of users gave Arbutus Biopharma an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.

CompanyUnderperformOutperform
Lyell ImmunopharmaOutperform Votes
14
48.28%
Underperform Votes
15
51.72%
Arbutus BiopharmaOutperform Votes
435
71.08%
Underperform Votes
177
28.92%

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by insiders. Comparatively, 4.0% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Lyell Immunopharma had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for Arbutus Biopharma. Lyell Immunopharma's average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lyell Immunopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arbutus Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Arbutus Biopharma beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks.

Get Lyell Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYEL vs. The Competition

MetricLyell ImmunopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$192.83M$7.07B$5.84B$9.15B
Dividend YieldN/A2.75%4.75%3.85%
P/E Ratio-0.895.4725.4719.00
Price / Sales1,574.74306.08447.5876.30
Price / CashN/A65.6738.0134.83
Price / Book0.276.717.644.62
Net Income-$234.63M$138.33M$3.18B$245.85M
7 Day Performance14.85%-2.61%-1.99%-2.68%
1 Month Performance21.75%-2.32%-0.42%-2.19%
1 Year Performance-71.28%-5.31%16.51%12.84%

Lyell Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LYEL
Lyell Immunopharma
2.1944 of 5 stars
$0.70
+6.2%
$1.00
+42.7%
-69.3%$192.83M$130,000.00-0.89270Upcoming Earnings
Gap Up
ABUS
Arbutus Biopharma
1.6499 of 5 stars
$3.33
-2.9%
$5.50
+65.2%
+18.9%$631.00M$18.14M-7.7490
IMTX
Immatics
1.6011 of 5 stars
$5.27
-2.4%
$16.67
+216.3%
-61.7%$629.03M$58.44M-7.98260
TYRA
Tyra Biosciences
1.7502 of 5 stars
$12.39
-2.2%
$30.50
+146.2%
-31.5%$626.93MN/A-7.7020Analyst Forecast
CRMD
CorMedix
1.325 of 5 stars
$10.29
+1.3%
$15.67
+52.3%
+211.7%$624.40M$60,000.00-12.7030News Coverage
Positive News
SANA
Sana Biotechnology
3.0617 of 5 stars
$2.73
-8.7%
$14.25
+422.0%
-62.3%$609.53MN/A-1.95380
RAPP
Rapport Therapeutics
1.8127 of 5 stars
$16.43
+1.9%
$35.00
+113.0%
N/A$601.01MN/A0.00N/AUpcoming Earnings
MNMD
Mind Medicine (MindMed)
2.3077 of 5 stars
$8.18
-1.0%
$26.33
+221.9%
+65.2%$599.84MN/A-3.6240Gap Up
CGEM
Cullinan Therapeutics
2.3347 of 5 stars
$10.10
-1.1%
$32.50
+221.8%
-47.1%$588.12MN/A-3.5630
PHAR
Pharming Group
2.9186 of 5 stars
$8.65
-1.5%
$27.00
+212.3%
-19.7%$588.12M$245.32M-33.25280Positive News
Gap Up
SEPN
Septerna
2.1659 of 5 stars
$13.17
+0.6%
$43.67
+231.6%
N/A$584.75MN/A0.00N/AAnalyst Downgrade
Analyst Revision
News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:LYEL) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners